Edition:
India

Otonomy Inc (OTIC.OQ)

OTIC.OQ on NASDAQ Stock Exchange Global Select Market

5.70USD
18 Jan 2018
Change (% chg)

-- (--)
Prev Close
$5.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
184,573
52-wk High
$21.15
52-wk Low
$2.80

Chart for

About

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment... (more)

Overall

Beta: --
Market Cap(Mil.): $104.55
Shares Outstanding(Mil.): 30.30
Dividend: --
Yield (%): --

Financials

BRIEF-Otonomy Sees 2017 Non-Gaap Expenses Totaling $73-$78 Million

* OTONOMY INC - EXPECTS GAAP OPERATING EXPENSES FOR 2017 TO TOTAL IN RANGE OF $95-$100 MILLION

09 Jan 2018

BRIEF-Otonomy Inc Immediately Discontinuing Commercial Support For Otiprio

* OTONOMY INC - ‍ IS IMMEDIATELY DISCONTINUING COMMERCIAL SUPPORT FOR OTIPRIO WHICH IS EXPECTED TO SIGNIFICANTLY REDUCE FUTURE OPERATING EXPENSES​

28 Nov 2017

BRIEF-Otonomy reports third quarter loss of $0.69 per share

* Otonomy reports third quarter 2017 financial results and provides corporate update

09 Nov 2017

BRIEF-Otonomy reports positive results from averts-2 phase 3 trial of otividex™ in patients with ménière's disease

* Otonomy reports positive results from Averts-2 Phase 3 trial of Otividex™ in patients with Ménière's disease

09 Nov 2017

BRIEF-Otonomy Inc says ‍non-commercial workforce reduced by one-third​

* Otonomy Inc - ‍* non-commercial workforce reduced by one-third​

13 Sep 2017

Otonomy pulls plug on ear drug, shares nosedive

Otonomy Inc said on Wednesday it suspended developing its drug for Meniere's disease, a chronic disorder of the inner ear, after it failed a late-stage trial, sending the drugmaker's shares plummeting in premarket trade.

30 Aug 2017

BRIEF-Otonomy reports results for Averts-1 phase 3 trial for Otividex

* Says ‍company is withdrawing spending guidance for year pending review of product pipeline plans

30 Aug 2017

Otonomy's ear disease drug fails late-stage study

Aug 30 U.S. drugmaker Otonomy Inc said on Wednesday its drug to treat Ménière's disease, a chronic disorder of the inner ear, missed the main goal in a late-stage study.

30 Aug 2017

BRIEF-Otonomy ‍reaffirms qtrly ‍net loss per share $0.77​

* Otonomy reports second quarter 2017 financial results and provides corporate update

04 Aug 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF83.42 +0.52
Auris Medical Holding AG (EARS.OQ) $0.51 --

Earnings vs. Estimates